期刊文献+

建立和实施罕用药制度的探讨 被引量:1

Establishment and operation of an orphan drug nmnagement system
原文传递
导出
摘要 实施罕用药制度可以显著提高罕见病患者治疗水平和生存质量,促进医药科技发展进步。作者参考国外的罕用药法规,汇集各国罕用药管理经验,包括罕用药认定、研制开发的扶持措施、市场保护、临床使用管理等,结合中国国情,讨论建立实施罕用药制度的方法策略和现实意义。 The orphan drug management system can significantly improve the quality of care and that of life of patients suffering from rare diseases, and accelerate the progress of medicinal science. With reference to laws and regulations on orphan drugs in other countries, the authors summarized the experiences of practicing the orphan drug management system in developed countries and regions, including certification of orphan drugs, supports for developing orphan drugs, market protection and clinic application management. Based on such studies, the authors discussed the feasibility and methodology of establishing an orphan drug management system in China, along with the significance of such a system.
出处 《中华医院管理杂志》 北大核心 2010年第8期601-604,共4页 Chinese Journal of Hospital Administration
关键词 罕用药 罕见病 罕用药制度 药事管理 Orphan drugs Rare disease Orphan drug management system
  • 相关文献

参考文献14

  • 1张建国.美国罕见病药物制度的背景及现状[J].药物流行病学杂志,2002,11(3):153-154. 被引量:4
  • 2陶勇,邵元福,张纯,郭澄,雷岚.日本的罕用药管理制度[J].中国药学杂志,2002,37(6):468-471. 被引量:12
  • 3张建国,荆汝泉,刘为义,单泰峰.台湾地区罕用药管理制度的简介[J].中华医院管理杂志,2008,24(4):255-257. 被引量:3
  • 4Linthorst G,Hollak C.European ordinance on orphan drugs:changes and threats[J].Ned Tijdschr Geneeskd,2003,147(4):143-145.
  • 5Scott D.Orphan drug programs/policies in Australia,Japan,and Canada[J].Drug Inf J,2001,35 (1):11-13.
  • 6Haffner ME.The Food and Drug Administration's Office of Orphan Products Development:incentives,grants,and special designations speed therapies for orphan diseases[J].Retina,2005,25(8 Suppl):89-90.
  • 7Heemstra H,Vrueh R.Predictors of orphan drug approval in the European Union[J].Eur J Clin Pharmacol,2008,64 (5):545-552.
  • 8Thoene JG.Orphan drugs and orphan tests in the USA[J].Community Genet,2004,7(4):169-172.
  • 9万仁甫,徐伟亚.建立医院罕见病信息管理制度的思考[J].中华医院管理杂志,2006,22(4):275-278. 被引量:11
  • 10Trouiller P,Rey J,Bouscharain P.Pharmaceutical development concerning diseases predominating in tropical regions:the concept of indigent drugs[J].Ann Pharm Fr,2000,58(1):43-44.

二级参考文献19

  • 1万仁甫,徐伟亚.建立医院罕见病信息管理制度的思考[J].中华医院管理杂志,2006,22(4):275-278. 被引量:11
  • 2王贤才(译).临床药物大典[M].青岛:青岛出版社,1994.248-300.
  • 3USA. Orphan Drug Act [M]. Pub Law USC, 1983, (4) : 97- 414.
  • 4Thamer M,Brenan N,Srmansky R. A cross national Comparison of orphan drug policies: implications for the US Orphan Drug Act[J]. J Health polit policy law, 1998,23(2) :265-269.
  • 5Meyers AS. Orphan Drugs:the current situation in the United States,Europe,and Asia[J]. Drug Inf J,1997,31(1) :101-105.
  • 6Meyers AS. History of the American Orphan Drug Act [R]. In ternational conference of rare disease and orphan drugs. Spain, 2000.
  • 7教育部.马克思主义政治经济学原理[M].北京:高等教育出版社,2004.153-180
  • 8[1]Orphan Drug Act. Pub Law, USC. 1983(97-414 as amended)
  • 9[2]The Orphan Drug Regulations. FDA.21 CFR Part 316, 1992,57FR62076
  • 10[3]John H. Orphan drug Law matures into medical mainstay. FDA Consumer, 1999,33(3):189

共引文献26

同被引文献5

  • 1卫生部.处方管理办法[S].2007.
  • 2卫生部.抗菌药物临床应用管理办法[S].2012-04-24.
  • 3卫生部.三级综合医院评审标准实施细则(2011年版)[S].2011.
  • 4卫生部.医疗机构药事管理暂行规定[S].2011:3.
  • 5龚时薇,张亮,金肆,李琳琳.提高我国罕见病患者用药可及性的管理策略研究[J].中华医院管理杂志,2010,26(2):126-130. 被引量:7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部